Omega-3 prescription market doubles in 3 Years

2.1 times more than 72 billion won in outpatient prescriptions in the first half of the year and 34.1 billion won in 2019

The statin compound has jumped sixfold in three years

Kuhnil

It is expected that generic companies will join and fierce competition is expected.

 

The market for Omega-3 is rapidly expanding.

 

The performance of outpatient prescriptions in the first half of the year has more than doubled in three years.

 

The prescription performance of Omega-3 and Statins has increased significantly.

 

It is predicted that competition in this market will become fiercer in the future, centering on the omega-3 and Statin complex.

 

According to UBIST, a pharmaceutical market research firm on the 17th, the size of outpatient prescriptions in the Omega-3 Rx market in the first half of this year is 72 billion won.

 

Compared to the first half of 2019, it has expanded 2.1 times.

 

This market is growing rapidly around 2020.

 

Based on the quarterly prescription amount, it was below 20 billion won until the third quarter of 2019, but it surpassed 20 billion won in the fourth quarter and exceeded 30 billion won in the second quarter of 2021.

 

In the second quarter of this year, it recorded 36.8 billion won, looking at the quarterly prescription amount of 40 billion won.

 

While the Omega-3 single system has steadily expanded its influence, the Omega-3 and statin complex has joined in earnest, driving the market expansion.

 

In fact, the prescription amount of omega-3 and statin composites in the first half of 2019 was only 2.4 billion won, but it increased 5.9 times in three years to 14.3 billion won this year.

 

In July 2017, Kuhnil was approved for Rosumega as the first omega 3+ Rosuvastatin complex.

 

Rosumega paid 600 million won in prescription that year, and increased to 4.1 billion won the following year.

 

After recording 6.7 billion won in 2019, it has become a large item that pays about 10 billion won in prescriptions since 2020.

 

With Rosumega on the market, other generic companies have joined the competition.

 

In December 2020, Jeil, Yuyu, Boryeung, Kyung Dong, Korea Prime, and Futecs were granted generic of the Omega 3·Rosuvastatin complex.

 

These products are manufactured by Kuhnil.

 

Last year, United joined the new competition.

 

Instead of commissioning production to Kuhnil, United challenged Kuhnil head-on through patent raids.

 

United, which won the patent dispute, released Atmeg Combigel Soft Cap in the second quarter of last year as an Omega 3+ Atorvastatin compound.

 

Atmeg Combigel is rapidly expanding its prescription performance with its release.

 

The prescription amount, which was 1.2 billion won in the second quarter of last year, increased seven times to 8.3 billion won in the second quarter of this year.

 

United plans to expand its performance to 20 billion won a year.

 

It is expected to have more intense competition in the future, centering on the Omega-3 and Statin complex.

 

Kuhnil was licensed for combination generics such as Atmeg Combigel, signaling competition.

 

Along with Kuhnil, Daehannupharm, Dongkoo Bio, Hutecs, and Penmix are expected to enter the market.

 

Kuhnil plans to produce their products on consignment.

 

United plan to face Atmeg Combigel with new dosages.

 

In addition to the existing Atorvastatin 10mg + Omega-3 1,000mg product, United has recently received approval for Atorvastatin 5mg + Omega-3 1000mg product.

 

On top of that, it plans to release additional medicines with the same ingredients through its affiliated company Korea Biochem.